Kenna Mathews

Kenna Mathews

Associate

Kenna Mathews is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she focuses on corporate and securities law.

Prior to attending law school, Kenna worked as a paralegal at Qualtrics where she negotiated SaaS transactions. During law school, Kenna worked as a business and legal analyst at University Growth Fund and participated in Brigham Young University's Law and Entrepreneurship Clinic.

Experience

Kenna Mathews is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she focuses on corporate and securities law.

Education

J.D., J. Reuben Clark Law School, Brigham Young University, 2024
B.S., Communication Disorders, Brigham Young University, 2019

Admissions

State Bar of California

Credentials

Education

J.D., J. Reuben Clark Law School, Brigham Young University, 2024
B.S., Communication Disorders, Brigham Young University, 2019

Admissions

State Bar of California

Corporate

Recent Insights

Client Highlights

On July 3, 2025, Zscaler, Inc. issued $1.725 billion aggregate principal amount of 0.00% convertible senior notes due 2028. The offering amount included the exercise in full of the option that Zscaler had granted to the initial purchasers to purchase up to an additional $225 million of notes. In connection with the offering, Zscaler entered into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions.

Learn More

Client Highlights

On June 16, 2025, Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced the close of its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven. The gross proceeds from the offering were approximately $230 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Enliven on the offering.

Learn More